Team:British Columbia/Achievements

From 2014.igem.org

(Difference between revisions)
 
(9 intermediate revisions not shown)
Line 1: Line 1:
{{:Team:British Columbia/Templates/MainHeader}}
{{:Team:British Columbia/Templates/MainHeader}}
<html>
<html>
-
  <div class="container">
 
-
      <div class="page-header">
 
-
          <h1>Achievements</h1>
 
<style>
<style>
.a,.g,.s,.b {
.a,.g,.s,.b {
Line 52: Line 49:
}
}
</style>
</style>
-
</html>
 
 +
  <div class="container">
 +
      <div class="page-header">
 +
          <h1>Achievements</h1>
<br>
<br>
-
<html>
 
-
<a name="top"></a>
 
<center>
<center>
-
<img src="https://static.igem.org/mediawiki/2013/9/9c/UBCigemGOLD.jpg" width="650">
+
<div style="height: 300px; width: 600px; float: center">
-
</center>
+
-
<br>
+
-
<br>
+
<div id="medals">
-
<p>
 
-
    <center><div style="height: 300px; width: 600px; float: center">
 
-
 
-
<ul class="a">
 
-
 
-
 
-
 
-
=='''Medal requirements'''==
 
-
<html>
 
-
 
-
<div id="medals">
 
<ul class="b">
<ul class="b">
-
<li>Submitted 40 and characterized 25 new <a href="https://2013.igem.org/Team:British_Columbia/Parts">biobrick parts</a></li>
+
<li> Submitted 12 new biobricks </li>
</ul>
</ul>
<ul class="s">
<ul class="s">
-
<li>Submitted Cas9 (<a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1129006">BBa_K1129006</a>) as our favorite functional part and showed evidence of immunity against phage using CRISPR components. </li>
+
<li> Demonstrated an activity with two of the biobricks </li>
-
<li>Obtained <a href="https://2013.igem.org/Team:British_Columbia/humanpractices/EthicsApproval">ethics approval</a> to <a href="https://2013.igem.org/Team:British_Columbia/humanpractices/ConductSurvey"> survey public’s perception</a> of GMOs with the aim to create a <a href="https://2013.igem.org/Team:British_Columbia/marketing">marketing strategy for a GM Yogurt</a>, following <a href="https://2013.igem.org/Team:British_Columbia/humanpractices/Interviews">interviews</a> with dairy industry and academic professionals </li>
+
<li> In testing the biobricks, discovered that a native membrane component in ''Caulobacter'' bounded minerals </li>  
</ul>
</ul>
<ul class="g">
<ul class="g">
-
<li>Improved 3 existing caffeine biosynthesis biobricks (<a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1129013"> BBa_K1129013 </a>, <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1129015"> BBa_K1129015</a>, <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1129017"> BBa_K1129017</a>) from TU Munich 2012 by replacing a yeast consensus sequence with a bacterial ribosome-binding site for prokaryotic engineering</li>
+
<li> Assessed commercialization feasibility from a regulatory, economic and integration perspective </li>
-
<li>Characterized previous iGEM parts (from <a href="https://2012.igem.org/Team:LMU-Munich"> TU Munich 2012</a>, <a href="https://2009.igem.org/Team:KULeuven/Project">KU Leuven 2009</a>, <a href="https://2007.igem.org/Edinburgh">Edinburgh 2007</a>) in <a href="https://2013.igem.org/Team:British_Columbia/Project/Vanillin">vanillin</a>, <a href="https://2013.igem.org/Team:British_Columbia/Project/Cinnamaldehyde">cinnamaldehyde</a> and <a href="https://2013.igem.org/Team:British_Columbia/Project/Caffeine">caffeine</a> biosynthesis pathways and were able to show functional data for substrate conversion. We are the only team to show data for <a href="https://2013.igem.org/Team:British_Columbia/Project/Vanillin#Data">vanillin</a> and <a href="https://2013.igem.org/Team:British_Columbia/Project/Cinnamaldehyde#Characterization">cinnamaldehyde</a> production in E. coli!</li>
+
</ul>
-
<li>Currently exploring the consequences of off-target activity in the CRISPR system. We are in the process of developing a resource (<a href="https://2013.igem.org/Team:British_Columbia/humanpractices/SpaceR">SPACE-R</a>) to assess the safety and specificity of individual spacer sequences.</li>
+
-
<li>Developed <a href="https://2013.igem.org/Team:British_Columbia/Modeling">comprehensive models</a> that (1) predict growth of CRISPR-expressing  E. coli cultures under phage predation, visualized using ‘Gro simulation’ (2) compute the cinnamaldehyde production following population tuning with various initial starting number of viruses</li>
+
</div>
</div>
-
</html>
 
 +
</div>
 +
 +
</div>
 +
 +
</div>
-
<html>
 
-
<div align="right"><a href="#top">Top of Page</a></div>
 
</html>
</html>

Latest revision as of 03:02, 18 October 2014

2014 UBC iGEM